1. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis 
Georg Griesinger, Robert Boostanfar, Keith Gordon, Davis Gates, Christine McCrary Sisk, Barbara J. Stegmann 
Reproductive BioMedicine Online 
Volume 33, Issue 1, Pages (July 2016)
DOI: /j.rbmo
Copyright © 2016 Reproductive Healthcare Ltd. Terms and Conditions

2. Figure 1
Pooled estimates for the differences in oocyte numbers and pregnancy and live-birth rates between corifollitropin and rFSH. *Adjusted for trial, centre, age, and body weight; **Adjusted for trial, region, age, and body weight. P-values describe the test for heterogeneity (P < 0.05 indicates heterogeneous differences across trials).
Reproductive BioMedicine Online  , 56-60DOI: ( /j.rbmo )
Copyright © 2016 Reproductive Healthcare Ltd. Terms and Conditions

3. Figure 2
Odds ratios for the development of ovarian hyperstimulation syndrome (OHSS), adjusted for the logistic regression model. P-values describe the test for heterogeneity (P < 0.05 indicates heterogeneous odds ratios across trials).
Reproductive BioMedicine Online  , 56-60DOI: ( /j.rbmo )
Copyright © 2016 Reproductive Healthcare Ltd. Terms and Conditions